|
|
Volumn 13, Issue 6, 2014, Pages 410-411
|
|
Tatiana Prowell
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOTOXIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
PERTUZUMAB;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
NEW DRUG;
ADVISORY COMMITTEE;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
STUDY DESIGN;
ARTICLE;
DRUG MONITORING;
HUMAN;
INTERVIEW;
METABOLISM;
METHODOLOGY;
NEOPLASM;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL MARKERS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG MONITORING;
DRUGS, INVESTIGATIONAL;
HUMANS;
INVESTIGATIONAL NEW DRUG APPLICATION;
NEOPLASMS;
RESEARCH DESIGN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84905160699
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4335 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|